Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,648 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,490)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06794957 | A Study of AL8326 in Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 158 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06480734 | Pneumonitis in Older Lung Cancer Patients After Radiotherapy(POLCAR) | active not recruiting | N/A | 62 | University Hospital Schleswig-HolsteinOTHER | 2 | Jan 16, 2025 | clinicaltrials |
| NCT03546361 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT05712902 | Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | active not recruiting | Phase 2 | 104 | Dizal PharmaceuticalsINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06751108 | Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients | active not recruiting | — | 2,000 | Seoul National UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05879068 | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | active not recruiting | Phase 2 | 99 | Biotheus Inc.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT02515760 | Tumor-specific T Cells in Lung Cancer | active not recruiting | N/A | 120 | University Hospital HeidelbergOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04794010 | A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer(FINN) | active not recruiting | — | 825 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06247280 | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation | active not recruiting | — | 2,001 | Yuhan CorporationINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03934866 | The SUMMIT Study: A Cancer Screening Study(SUMMIT) | active not recruiting | — | 13,035 | University College, LondonOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | active not recruiting | Phase 3 | 531 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Dec 3, 2024 | clinicaltrials |
| NCT04923906 | Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations | active not recruiting | Phase 3 | 624 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04699721 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC | active not recruiting | Phase 2 | 60 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06700421 | Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | active not recruiting | Phase 2 | 32 | Wei ZhouOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01553942 | Afatinib With CT and RT for EGFR-Mutant NSCLC | active not recruiting | Phase 2 | 19 | Massachusetts General HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT04687241 | Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations | active not recruiting | Phase 3 | 192 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04127110 | Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients(ALKALINE) | active not recruiting | Phase 2 | 68 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Nov 5, 2024 | clinicaltrials |
| NCT05566041 | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer(REPLATINUM) | active not recruiting | Phase 3 | 292 | EpicentRx, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT02611570 | LDCT Screening in Non-smokers in Taiwan | active not recruiting | — | 12,000 | Academia Sinica, TaiwanOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05400070 | Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC | active not recruiting | Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT04806399 | Improving Utilization of Lung Cancer Screening in Underserved PA Populations | active not recruiting | N/A | 2,500 | American College of RadiologyOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06616909 | Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences | active not recruiting | N/A | 120 | National Taiwan University HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06569420 | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | active not recruiting | Phase 3 | 275 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT04685070 | Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 56 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05015010 | Alectinib in Neo-adjuvant Treatment of Stage III NSCLC(ALNEO) | active not recruiting | Phase 2 | 33 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06542731 | An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 42 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04545710 | Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance | active not recruiting | Phase 2 | 18 | University of California, San DiegoOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT04143607 | ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC | active not recruiting | Phase 3 | 337 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT03299478 | Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer(TNM-I) | active not recruiting | — | 865 | University Hospital of North NorwayOTHER | 2 | Jun 11, 2024 | clinicaltrials |
| NCT05982574 | Tumor Microenvironment | active not recruiting | — | 300 | University Hospital HeidelbergOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT03870464 | LIFE - Lung Cancer, Immunotherapy, Frailty, Effect | active not recruiting | — | 150 | University of Southern DenmarkOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06391944 | JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations | active not recruiting | Phase 2 | 161 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05383716 | Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy(NeoP) | active not recruiting | Phase 2 | 80 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT05219734 | MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment(MARIA) | active not recruiting | — | 400 | Invitae CorporationINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05636592 | Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small Cell Lung Cancer | active not recruiting | — | 250 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT02247453 | Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study(BIOMILD) | active not recruiting | N/A | 4,119 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04300244 | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma(NIPU) | active not recruiting | Phase 2 | 118 | Åslaug HellandOTHER | 5 | Feb 29, 2024 | clinicaltrials |
| NCT04392505 | Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study(DART) | active not recruiting | Phase 2 | 100 | Oslo University HospitalOTHER | 4 | Feb 29, 2024 | clinicaltrials |
| NCT05069792 | Utrecht COhort for Lung Cancer Outcome Reporting and Trial Inclusion (U-COLOR)(U-COLOR) | active not recruiting | — | 2,000 | UMC UtrechtOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05537701 | Tissue Eosinophils in Non-Small Cell Lung Cancer (the TEN Study)(TEN) | active not recruiting | — | 316 | Centre Hospitalier Universitaire de LiegeOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT01475500 | Nashville Early Diagnosis Lung Cancer Project | active not recruiting | — | 480 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT03066297 | Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer(OREX-IA) | active not recruiting | — | 1,018 | Samsung Medical CenterOTHER | 1 | Dec 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2025source: clinicaltrials